Effect of iberdomide on cutaneous manifestations in systemic lupus erythematosus: A randomized phase 2 clinical trial [0.03%]
伊布利司治疗系统性红斑狼疮皮损的疗效：随机Ⅱ期临床试验
Victoria P Werth,Joan T Merrill,Richard Furie et al.
Victoria P Werth et al.
Background: Iberdomide, a cereblon modulator, promotes degradation of transcription factors Ikaros and Aiolos. Objective: Evaluate iber...
Association of human leukocyte antigen allelic variants with hidradenitis suppurativa across Fitzpatrick skin types: A cross-sectional analysis [0.03%]
人白细胞抗原等位基因变异与不同Fitzpatrick皮肤类型中汗腺炎的相关性：横断面分析
Aaron Bao,Jack Kollings,Emily Ma et al.
Aaron Bao et al.
A retrospective multicenter cohort study of differences in clinical characteristics of Infantile Hemangiomas in preterm and term infants: Prematurity increases risk of permanent cutaneous sequelae [0.03%]
一项关于早产儿和足月婴儿血管瘤临床特征差异的多中心回顾性队列研究：早产增加永久皮肤后遗症的风险
Flora E Bradley,Esteban Fernández Faith,Sonal D Shah et al.
Flora E Bradley et al.
Background: We observed many preterm infants with unexpectedly thick infantile hemangiomas (IH), a subtype known to be associated with an increased risk of scarring. ...
Drug samples in dermatology: A focus on underserved and under-resourced patients [0.03%]
皮肤病学中的药物样本：关注弱势和资源匮乏的患者
Christopher Wachuku,Jennifer Lucas,Christina Cruz et al.
Christopher Wachuku et al.
Seasonal trends in drug reaction with eosinophilia and systemic symptoms [0.03%]
药物过敏反应合并嗜酸性粒细胞增多和系统症状的季节变化趋势分析
Amar D Desai,Cristina Thomas
Amar D Desai
Jorge Ocampo-Candiani
Jorge Ocampo-Candiani
Enhancing skin of color education in a dermatology residency program through a journal club: A survey study [0.03%]
通过期刊俱乐部增强皮肤病学住院医师项目中关于肤色皮肤的教育：一项调查研究
Nasro A Isaq,Chelsea N Handfield,Nahid Y Vidal
Nasro A Isaq
Outcomes of the American Board of Dermatology focused Practice Improvement program 2016-2023 [0.03%]
2016年至2023年美国皮肤病学会重点关注改善计划的实施效果
Erik Stratman,Stanley Miller,Murad Alam et al.
Erik Stratman et al.
Background: Board-certified dermatologists experience diverse practice gaps. Objective: Identify the top self-selected focused Practice...
Tumor characteristics and outcomes of malignant melanomas on the genitalia [0.03%]
外生殖器恶性黑色素瘤的临床病理特征及预后分析
Ajay N Sharma,Jagmeet S Arora,Nahid Y Vidal et al.
Ajay N Sharma et al.
Outcomes of down-titration in patients with severe scalp alopecia areata initially treated with baricitinib 4-mg: Week 152 data from BRAVE-AA2 [0.03%]
BRAVE-AA2研究第152周数据：巴利昔单抗初始治疗重度头皮型 alopecia areata的疗效下降情况及其结局
Brett King,Manabu Ohyama,Maryanne Senna et al.
Brett King et al.
Background: Baricitinib, an oral selective Janus kinase inhibitor, is approved to treat adults with severe alopecia areata (AA). Objective: ...